Supplementary Figures 1-6, Table 1, Methods from Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai(National Institutes of Health), Yves Pommier(National Institutes of Health)
Cited by 0
Related Papers
Human topoisomerases and their roles in genome stability and organization
|Nature Reviews Molecular Cell Biology|2022|446
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
|Oncotarget|2016|292
Inhibition of Histone Deacetylase in Cancer Cells Slows Down Replication Forks, Activates Dormant Origins, and Induces DNA Damage
|Cancer Research|2010|155
Optimal function of the DNA repair enzyme TDP1 requires its phosphorylation by ATM and/or DNA‐PK
|The EMBO Journal|2009|147